MedPath

Effect of omega 3 fatty acid (DHA) Supplementation during pregnancy on newborn birth weight and gestational age .

Phase 3
Completed
Registration Number
CTRI/2013/04/003540
Lead Sponsor
Department of Science and Technology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
957
Inclusion Criteria

a) 18-35 y old pregnant women (singleton) at <20 weeks of gestation (calculated from the last menstrual period or by ultrasound in 1st trimester as suggested by study physician/team).

b) Willing to participate in the study and provide all measurements for her and the offspring including anthropometry, dietary assessment and questionnaires plus the biochemical parameters (blood, breast milk)

c) Witnessed informed consent signed by mother.

d) Plans to deliver at the study hospital (under JNMC, Belgaum)

Exclusion Criteria

a) Women allergic (if aware) to any of the test products.

b) Women with any known history of bleeding tendency or thrombosis (if aware).

c) Women with high-risk pregnancies â??

- any bleeding episode in the current pregnancy;

- hypertension;

- diagnosed heart disease;

- cancer;

- stroke;

- diabetes

d) Women consuming omega-3 supplements or having used these in 3 months preceding the intervention period.

e) Reported participation in another biomedical trial 3 months before the start of the study or during the study (not to get the results of the present study contaminated).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Birth Weight <br/ ><br>Gestational AgeTimepoint: At delivery
Secondary Outcome Measures
NameTimeMethod
Head circumference of baby <br/ ><br>Crown-heel length <br/ ><br>APGAR scoresTimepoint: At delivery
© Copyright 2025. All Rights Reserved by MedPath